World Journal of Nephrology
Clinical trials have demonstrated the efficacy of finerenone, a highly selective, non-steroidal MRA, in reducing renal and CV outcomes in patients with long-standing T2DM.
A. Bashar, M. Kamrul-Hasan, K. Mahajan et al.
· 0 citations